Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05976750 · ClinicalTrials.gov registry record
Air Optix® Night and Day® Aqua Daily Wear
A clinical trial, sponsored by Alcon Research.
- Completed
- Registry status
- 102
- Enrollment target
NCT05976750: Completed study, sponsored by Alcon Research.
NCT05976750 is a clinical trial that has completed, run by Alcon Research. The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05976750 has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- 102 participants
- Enrollment target
Study Summary
The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term performance and safety of Air Optix® Night and Day® Aqua (AONDA) contact lenses in a real-world setting when worn as daily wear for vision correction.
Primary Outcome
The subject's chart will be reviewed for distance visual acuity.
Interventions
- DEVICE Balafilcon A contact lenses
- DEVICE Lotrafilcon A contact lenses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2024-07-30 |
What the finished NCT05976750 record still lists
NCT05976750 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Balafilcon A contact lenses is the first listed.
NCT05976750 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05976750 about?
NCT05976750 is a clinical study titled "Air Optix® Night and Day® Aqua Daily Wear". The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term performance and safety of Air Optix® Night and Day® Aqua (AONDA) contact lenses in a real-world setting when worn as daily wear for vision correction.
What is the current status of trial NCT05976750?
This trial is currently completed. The enrollment target is 102 participants. The study started on 2023-10-03. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT05976750?
The interventions under investigation include: Balafilcon A contact lenses (DEVICE), Lotrafilcon A contact lenses (DEVICE).
Who is sponsoring clinical trial NCT05976750?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI